Topica Pharma grabs $27M B round for topical antifungal drug

Aiming to improve the treatment of nail fungus, Topica Pharmaceuticals has rallied venture investors for a $27 million Series B round of financing. The firm plans to use the capital for a 300-patient Phase IIb/III trial of luliconazole, testing to see whether the topical antifungal agent can cure toenail fungus at 52 weeks of treatment. The Palo Alto, CA-based company says its agent is able to penetrate nails and settle into the nail bed, with limited side effects due to low systemic absorption. Article

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.